Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2022

View Archived Issues

New monoglyceride lipase inhibitors identified at Roche

LG Chem discovers diacylglycerol O-acyltransferase 2 inhibitors

Seoul National University Hospital patents triglyceride-lowering peptides

Friedrich-Alexander-University Erlangen-Nuremberg presents mu-opioid receptor agonists

New USP7 inhibitors identified at Shouyao Holdings

Elicio Therapeutics' TLR9 agonist AMP-CpG induces potent immune and antitumoral effects

PF-07038124: a topical PDE4 inhibitor for atopic dermatitis and plaque psoriasis

LNP formulation development and production service launched by eTheRNA Manufacturing

Artelo collaborates with Trinity College Dublin to better understand FABP inhibition in cancer

Flavonoids as nuclear receptor 4A1 ligands for treating rhabdomyosarcoma

Novel NR4A1 antagonists show antitumor activity in syngeneic mouse model of colon cancer

Gain-of-function study identifies T-cell boosters

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...